New Data from Johnson & Johnson Vision Highlights the Need and Potential Standards for Evidence-Based Decision-Making in Myopia

Source: Johnson & Johnson Vision

Johnson & Johnson Vision announced that Noel A Brennan, PhD, the company’s Global Platform Lead for Myopia Control, will present data on myopia progression and investigational methods to control it at the 2018 American Academy of Optometry Annual Meeting, held November 7-10 in San Antonio, Texas.

“Despite the exponential rise in prevalence of myopia, few strategies used for myopia control have proven to be effective and it does not receive the same scientific attention as other eye conditions,” Dr. Brennan said. “Given the lack of a globally approved modality for myopia control, eye care professionals around the world rely significantly on their expertise and judgment when it comes to intervention, often without evidence-based data that would further inform their treatment decisions for patients.”

The two meta-analyses being presented at the meeting include:

Data for evidence-based decisions about myopia control

In “Evidence-based Efficacy of Myopia Control Interventions,” Dr. Brennan evaluated the efficacy of current myopia treatments, including 0.01% atropine, orthokeratology, multizone soft contact lenses, spectacles (E-line, DIMS), and increased outdoor time, in 32 published studies.

The analysis found that the greatest treatment effects reported to date are 0.43mm of axial elongation and a refractive error of 1.05D – effects that may be limited to certain patients and subject to rebound.  In the world of evidence-based reporting of medical data, these values represent a best-case scenario and a basis for education of practitioners and patients to help manage expectations around myopia treatment and management. The analysis also reports that 0.01% atropine is clinically ineffective at controlling axial elongation.

Dr. Brennan will present this poster on Friday, November 9, from 10:00 a.m. – 12:00 p.m. in the Exhibit Hall of the Henry B. Gonzalez Convention Center.

Axial length as a metric for myopia progression in children

“Influence of Age and Race on Axial Elongation in Myopic Children” is the first meta-analysis of axial elongation in myopic children.  Data was collated from 63 studies of pediatric myopia progression and Dr. Brennan developed new equations that instead of refractive progression looked at myopic subjects’ axial length – a repeatable measurement that can be obtained without cycloplegia, which is the paralysis of the ciliary muscle of the eye preventing the curvature of the lens from being able to focus on nearby objects. 

As efforts to achieve myopia control become more widespread, axial length measurement has the potential to become a more common metric for progression to help practitioners better evaluate and judge the efficacy of interventions for their patients.

“This work puts a stake in the ground around which future expectations for myopia control efficacy can be assessed and how individual patient progress can be gauged,” concluded Dr. Brennan.

Dr. Brennan will present this paper on Thursday, November 8, at 1:00 p.m. in Room 304 of the Henry B. Gonzalez Convention Center.

Related Content